Author Index

Abouchacra K, 399
Adams K, 367
Adams SW, 275
Alchediak T, 292
Aleksandrovsky IV, 417
Amos N, 112

Barrett KA, 444
Barry SJ, 105
Beauregard Y, 315
Becker TR, 47
Besing J, 399
Borgsmiller P, 134
Bourgeois M, 275
Burchfield SB, 434
Byrne D, 25, 163

Calder JH, 263
Callison DM, 285
Carr MM, 371
Chambers JA, 95
Champagne SC, 315
Champlin CA, 95
Chen JM, 59
Chermak GD, 78, 452
Chertoff M, 127
Chmiel R, 67
Christensen LA, 292
Clark JL, 426
Cohlan B, 134
Cord MT, 165, 398
Cornelisse LE, 216
Cox LC, 35, 41, 272
Crandell CC, 227
Cranford JL, 385
Cruickshanks KJ, 191

DeBus B, 1
Disher MJ, 251
Doggett S, 361
Durieux-Smith A, 315
Durrant JD, 275
Dybala PD, 426

Edwards BM, 251
Elisevich KV, 87
El-Kholy W, 179
Emmer MB, 380

Fabry DA, 342
Fallis-Cunningham R, 299
Fanning R, 380
Fausti SA, 147
Ferraro J, 127
Fortune T, 162
Frey RH, 147
Fulfs JM, 444

Gans D, 361
Ge NN, 121
Gfeller K, 1
Giguère C, 315
Griffiths SK, 227

Harkrider AW, 410
Hartmann WM, 466
Hayden D, 147
Hayes DE, 59
Helfer KS, 234
Henderson J, 87, 263
Henry JA, 147
Hickson L, 163
Homnick DN, 172
Horn KL, 285
Hurley RM, 20
Hymel MR, 385

Jacobson GP, 87, 153, 263
Jerger J, 67, 312, 380

Katbamna B, 172
Keith RW, 299, 311
Kessler JL, 272
Kileny PR, 251
Klein BEK, 191
Klein R, 191
Knutson JF, 1
Koehnke J, 399
Kryter KD, 141

Lasky RE, 47
Lehman ME, 243
Letowski T, 399
Levine A, 41
Lindley GA IV, 209
Littman TA, 257

MacDonald CB, 35, 41, 272
Magruder A, 257
Mann T, 367
Marks JH, 172
Martin FN, 95, 312, 410
Marzolf CA, 243
McCall S, 127
McCullough JK, 417
Miller MH, 311
Miller SM, 216
Moran LM, 315
Morehouse CR, 292
Moushegian G, 426
Musiek FE, 452

Nerbonne MA, 243
Newman CW, 153
Noble W, 25
Nondahl DM, 191

Orchik DJ, 121

Palmer CV, 209, 275
Parent TC, 67
Parkinson AJ, 179
Parthasarathy TK, 134
Pearlstein R, 263
Phillips DP, 199, 371
Phillips DS, 147
Picton TW, 315
Plyler PN, 434
Pope ML, 221
Potts LG, 342
Powell TW, 292
Pugh KC, 227

Rakerd B, 466
Rintelmann WF, 112
Roberson JB Jr, 305
Rock J, 263
Rossi M, 275

Sandlin RE, 342
Sandridge SA, 153
Scheller T, 162
Scollie SD, 216
Seewald RC, 216
Seikel JA, 78, 452
Shea JJ Jr, 121
Silio M, 292
Silman S, 380
Silverman CA, 380
Simpson TH, 112
Sinclair S, 25
Smith BJ, 87
Somers EK, 78
Stach BA, 305
Stein RL, 361
Stewart M, 243
Strother DR, 257
Stuart A, 199, 385
Surr RK, 165, 398

Telian SA, 251
Thelin JW, 434
Traynham WA, 452
Tweed TS, 191
Tyler RS, 179

Valente M, 342
Vander Velde TJ, 466

Walden BE, 165, 398
Walsh FP, 35
Warnick RE, 299
Westerberg BD, 305
Whittingham J, 315
Wiley TL, 191
Wilson RH, 417
Wiorek L, 47
Witt S, 1
Woodworth G, 1

Zapala DA, 332

Author Index

Abouchacra K, 399
Adams K, 367
Adams SW, 275
Alchediak T, 292
Aleksandrovsky IV, 417
Amos N, 112

Barrett KA, 444
Barry SJ, 105
Beauregard Y, 315
Becker TR, 47
Besing J, 399
Borgsmiller P, 134
Bourgeois M, 275
Burchfield SB, 434
Byrne D, 25, 163

Calder JH, 263
Callison DM, 285
Carr MM, 371
Chambers JA, 95
Champagne SC, 315
Champlin CA, 95
Chen JM, 59
Chermak GD, 78, 452
Chertoff M, 127
Chmiel R, 67
Christensen LA, 292
Clark JL, 426
Cohlan B, 134
Cord MT, 165, 398
Cornelisse LE, 216
Cox LC, 35, 41, 272
Crandell CC, 227
Cranford JL, 385
Cruickshanks KJ, 191

DeBus B, 1
Disher MJ, 251
Doggett S, 361
Durieux-Smith A, 315
Durrant JD, 275
Dybala PD, 426

Edwards BM, 251
Elisevich KV, 87
El-Kholy W, 179
Emmer MB, 380

Fabry DA, 342
Fallis-Cunningham R, 299
Fanning R, 380
Fausti SA, 147
Ferraro J, 127
Fortune T, 162
Frey RH, 147
Fulfs JM, 444

Gans D, 361
Ge NN, 121
Gfeller K, 1
Giguère C, 315
Griffiths SK, 227

Harkrider AW, 410
Hartmann WM, 466
Hayden D, 147
Hayes DE, 59
Helfer KS, 234
Henderson J, 87, 263
Henry JA, 147
Hickson L, 163
Homnick DN, 172
Horn KL, 285
Hurley RM, 20
Hymel MR, 385

Jacobson GP, 87, 153, 263
Jerger J, 67, 312, 380

Katbamna B, 172
Keith RW, 299, 311
Kessler JL, 272
Kileny PR, 251
Klein BEK, 191
Klein R, 191
Knutson JF, 1
Koehnke J, 399
Kryter KD, 141

Lasky RE, 47
Lehman ME, 243
Letowski T, 399
Levine A, 41
Lindley GA IV, 209
Littman TA, 257

MacDonald CB, 35, 41, 272
Magruder A, 257
Mann T, 367
Marks JH, 172
Martin FN, 95, 312, 410
Marzolf CA, 243
McCall S, 127
McCullough JK, 417
Miller MH, 311
Miller SM, 216
Moran LM, 315
Morehouse CR, 292
Moushegian G, 426
Musiek FE, 452

Nerbonne MA, 243
Newman CW, 153
Noble W, 25
Nondahl DM, 191

Orchik DJ, 121

Palmer CV, 209, 275
Parent TC, 67
Parkinson AJ, 179
Parthasarathy TK, 134
Pearlstein R, 263
Phillips DP, 199, 371
Phillips DS, 147
Picton TW, 315
Plyler PN, 434
Pope ML, 221
Potts LG, 342
Powell TW, 292
Pugh KC, 227

Rakerd B, 466
Rintelmann WF, 112
Roberson JB Jr, 305
Rock J, 263
Rossi M, 275

Sandlin RE, 342
Sandridge SA, 153
Scheller T, 162
Scollie SD, 216
Seewald RC, 216
Seikel JA, 78, 452
Shea JJ Jr, 121
Silio M, 292
Silman S, 380
Silverman CA, 380
Simpson TH, 112
Sinclair S, 25
Smith BJ, 87
Somers EK, 78
Stach BA, 305
Stein RL, 361
Stewart M, 243
Strother DR, 257
Stuart A, 199, 385
Surr RK, 165, 398

Telian SA, 251
Thelin JW, 434
Traynham WA, 452
Tweed TS, 191
Tyler RS, 179

Valente M, 342
Vander Velde TJ, 466

Walden BE, 165, 398
Walsh FP, 35
Warnick RE, 299
Westerberg BD, 305
Whittingham J, 315
Wiley TL, 191
Wilson RH, 417
Wiorek L, 47
Witt S, 1
Woodworth G, 1

Zapala DA, 332

Subject Index

AABR. *See* Automated auditory brainstem response
Abbreviated Profile of Hearing Aid Benefit (APHAB), 67–77, 342–356, 360
ABR. *See* Auditory brainstem response
AC. *See* Air conduction
Acoustic coupling, 434–442
Acoustic otoscope, 35–40
Acoustic radiation, 410–416
Acoustic transducer assembly (ATA), 426–432
Acquired immune deficiency syndrome. *See* AIDS
Action potential, 121–125
ADHD. *See* Attention deficit hyperactivity disorder
AEP. *See* Auditory evoked potential
AFT-R. *See* Auditory Fusion Test-Revised
Aging
  unaided ear effect and, 20–23
  word recognition and, 20–23, 191–198
Aided thresholds, 315–330
AIDS (acquired immune deficiency syndrome), 292–298
Air conduction (AC), 410–416
ALGO2™ neonatal automated auditory brainstem response, 426–432
Alzheimer disease, 275–282, 284
American National Standards Institute (ANSI), 112–120
Amplifier, 105–110
Analog hearing aids, 342–356, 358–360
ANSI. *See* American National Standards Institute
Antiviral therapy, 292–298
APHAB. *See* Abbreviated Profile of Hearing Aid Benefit
ATA. *See* Acoustic transducer assembly
Attention deficit hyperactivity disorder (ADHD), 78–84
Audiologic practice, 95–104
Auditory brainstem response (ABR)
  click stimuli and, 127–133
  in neonates, 134–139, 426–432
Auditory canal, 410–416
Auditory event-related potential, 385–395
Auditory evoked potential (AEP), 87–93, 385–395, 444–451
Auditory function, 299–304, 305–310
Auditory Fusion Test-Revised (AFT-R), 299–304
Auditory processing assessment practices, 452–465
Auditory professional education, 452–465
Auditory steady state response, 315–330
Automated auditory brainstem response (AABR), 426–432
AZT. *See* Zidovudine

BC. *See* Bone conduction
Behind-the-ear (BTE) hearing aids, 434–442
Binaural detection threshold, 399–407
Bone conduction (BC), 59–66, 410–416
Brain map study, 385–395
BTE. *See* Behind-the-ear (BTE) hearing aids

CAPD. *See* Central auditory processing disorder
Central auditory processing disorder (CAPD)
  assessment of, 452–465
  behavioral signs of, 78–84
  with bilateral temporal lobe tumors, 299–304
Central hyperexcitability, 375–377
Central nervous system (CNS), 305–310
Cerebellopontine angle (CPA), 251–255
Children
  with cystic fibrosis, 172–178, 249
  hearing loss in, 179–188, 285–290, 314
  HIV in, 292–298
  predicting ototoxic damage in, 257–262
  using hearing aids, 315–330
  See also Infants
CIC. *See* Completely-in-the-canal (CIC) aids
Click stimuli, 121–125, 127–133
CNS. *See* Central nervous system
Cochlear implants, 1–18, 179–188
Completely-in-the-canal (CIC) aids, 59–66, 216–220
Compression amplification, 163
Conduction, 59–66, 410–416
Connected Speech Test (CST), 165–171
Consonants, 162
Contour Test, 209–214
Contralateral suppression, 172–178, 249
Coupling, 434–442
CPA. *See* Cerebellopontine angle
CST. *See* Connected Speech Test
Cystic fibrosis, 172–178, 249

ddl. *See* Didanosine
Deafness. *See* Hearing loss
Didanosine (ddl), 292–298
Digital hearing aids, 342–356, 358–360
Distortion-product otoacoustic emissions (DPOAEs)
  contralateral suppression of, 172–178, 249
  ototoxicity prediction using, 257–262
  probabilistic detection of, 332–340
DPOAEs. *See* Distortion-product otoacoustic emissions
Dysacusis, 371–377

EAC. *See* External auditory canal
Earmold, 25–33
ECMO. *See* Extracorporeal membrane oxygenation
Education, professional, 452–465
Elderly
  auditory event-related potentials in, 385–395
  See also Older adults
Electromagnetic coupling, 434–442
Electroneurography (ENoG), 41–46, 121–125

EMLA. *See* Eutectic Mixture of Local Anesthetic
ENoG. *See* Electroneurography
EOAEs. *See* Evoked otoacoustic emissions
ERP. *See* Event-related potential
Eutectic Mixture of Local Anesthetic (EMLA), 41–46
Event-related potential (ERP), 385–395
Evoked otoacoustic emissions (EOAEs), 251–255
External auditory canal (EAC), 410–416
Extracorporeal membrane oxygenation (ECMO), 47–57, 367–369

Facial nerve paralysis, 373–375
FIT. *See* Fusion at Inferred Threshold (FIT) test
Frequency transposition hearing aids, 67–77
Full-shift testing, 118–119
Fusion at Inferred Threshold (FIT) test, 221–226

Gamma band response (GBR), 87–93
GBR. *See* Gamma band response
Gender, 361–365, 444–451

HCP. *See* Hearing conservation program
Hearing aids
  amplification circuits, 105–110
  behind-the-ear, 434–442
  benefit from, 165–171, 398
  in children, 315–330
  completely-in-the-canal, 59–66, 216–220
  digital versus analog, 342–356, 358–360
  frequency transposition versus conventional, 67–77
  in-the-ear, 434–442
  in older females, 361–365
  ReSound BT2, 165–171
  telephone and, 434–442
Hearing conservation program (HCP), 112–120
Hearing handicap, 141–145
Hearing in Noise Test (HINT), 342–356, 359
Hearing loss
  in Alzheimer disease, 275–282, 284
  in children, 179–188, 257–262, 285–290, 314
  Contour Test in, 209–214
  in infants, 47–57
  sensorineural, 20–23, 251–255, 367–369
  simulated, 199–206
HFO. *See* High-frequency oscillatory (HFO) therapy
High-frequency oscillatory (HFO) therapy, 47–57
High-frequency thresholds, 25–33, 147–152
HINT. *See* Hearing in Noise Test
HIV (human immunodeficiency virus), 292–298
Human immunodeficiency virus. *See* HIV
Hyperacusis, 371–377, 399
Hyperexcitability, 375–377

Infants
  hearing loss in, 47–57
  See also Neonates
In-the-ear (ITE) hearing aids, 434–442
ITE. *See* In-the-ear (ITE) hearing aids

Large vestibular aqueduct syndrome (LVAS), 285–290, 314
LDL. *See* Loudness discomfort level
Loudness discomfort level (LDL), 371–377, 399
LVAS. *See* Large vestibular aqueduct syndrome

Mastoid, 410–416
Meatal plate, 381
Median sagittal plane (MSP), 466–478
MEE. *See* Middle ear effusion
Meniere's disease, 121–125
Meningioma, 251–255
Middle ear effusion (MEE), 35–40
Mismatch negativity (MMN), 444–451
MMN. *See* Mismatch negativity
MSP. *See* Median sagittal plane
MTN. *See* Multitalker noise
Multichannel cochlear implants, 179–188
Multitalker noise (MTN), 399–407
Music recognition, 1–18

Neonates
  auditory brainstem response in, 134–139, 426–432
  extracorporeal membrane oxygenation and, 47–57, 367–369
Noise, 342–356, 358, 359, 399–407
N1 response, 87–93
Nystagmus, 263–271

OAEs. *See* Otoacoustic emissions
Older adults
  hearing aids in, 361–365
  speech recognition by, 234–241
  See also Elderly
Open earmold, 25–33
Oscillatory therapy, 47–57
Otitis media, 272–274
Otoacoustic emissions (OAEs)
  transient evoked, 251–255
  See also Distortion-product otoacoustic emissions
Otoscope, 35–40
Ototoxicity, 147–152, 257–262

Pain, 41–46
Paralysis, facial nerve, 373–375
Paraphrasing, 243–248
PHAB. *See* Profile of Hearing Aid Benefit
Phonophobia, 371–377
Pitch-Pattern Sequence Test (PPST), 299–304
Potential(s)
  action, 121–125
  auditory event-related, 385–395
  auditory evoked, 87–93, 385–395, 444–451
PPST. *See* Pitch-Pattern Sequence Test
Prelingual hearing loss, 179–188
Presbyacusis, 466–478
Professional auditory processing education, 452–465
Profile of Hearing Aid Benefit (PHAB), 165–171

Radiation, 410–416
Real-ear aided response (REAR), 216–220
Real-ear measurements, 216–220, 426–432
REAR. *See* Real-ear aided response

Recovery nystagmus, 263–271
ReSound BT2 hearing aid, 165–177
RPIT. *See* Russian Picture Identification Task
Russian Picture Identification Task (RPIT), 417–424, 425

Sagittal plane, 466–478
SCAN-A test, 299–304, 311
SDMT. *See* Symbol Digit Modality Test
SENSO digital hearing aid, 342–356, 358–360
Sensorineural hearing loss (SNHL), 20–23, 251–255, 367–369
Sentence identification, 227–232
Simulated hearing loss, 199–206
SNHL. *See* Sensorineural hearing loss
Sound localization, 25–33, 466–478
Spatial audiometry, 399–407
Speech
  competition, 385–395
  spectrum noise, 399–407
  See also Speech recognition
Speech Perception in Noise (SPIN), 342–356, 358
Speechreading, 243–248
Speech recognition
  by older adults, 234–241
  suprathreshold, 380–383, 417–424, 425
  threshold, 227–232
SPIN. *See* Speech Perception in Noise
Spondaic word, 399–407
SSI. *See* Synthetic Sentence Identification (SSI) test
Suprathreshold speech recognition, 380–383, 417–424, 425
Symbol Digit Modality Test (SDMT), 299–304
Synthetic Sentence Identification (SSI) test, 227–232

Telephone
  ear effect, 380–383
  hearing aids and, 434–442
Temporal distortion, 199–206
Temporal lobe tumors, 299–304
TEOAEs. *See* Transient evoked otoacoustic emissions
THI. *See* Tinnitus Handicap Inventory
Timbral recognition, 1–18
Tinnitus, 153–158, 160
Tinnitus Handicap Inventory (THI), 153–158, 160
Tobramycin, 172–178, 249
Transient evoked otoacoustic emissions (TEOAEs), 251–255
Tuberculosis, 305–310
Tumors, temporal lobe, 299–304
Tympanometry, 272–274

Unaided ear effect, 20–23

Vestibular system, 263–271, 285–290, 314
Vowel perception, 179–188

Wave V latency, 134–139
Widex SENSO digital hearing aid, 342–356, 358–360
Word
  paraphrasing and repetition, 227–232
  spondaic, 399–407
Word recognition
  aging and, 20–23, 191–198
  competing messages and, 191–198
  for Russian-speaking patients, 417–424, 425
  temporal distortion and, 199–206

Zidovudine (AZT), 292–298